Preparation of recombinant reteplase inclusion bodies in E. coli and its refolding in vitro

The vector with the gene of recombinant reteplase(rt-PA) was cloned into E. coli BL21(DE3) cells. Over-expression of rt-PA as inclusion bodies was obtained, and renaturation of rt-PA in vitro was investigated. Firstly, single factor experiments were conducted to optimize refolding conditions, including refolding buffer p H, GSH concentration, ratio of GSH to GSSG, rt-PA concentration. On this basis, high concentration protein refolding was further investigated by orthogonal experimental design. Fermentation broth with 1.7 g crude inclusion bodies per liter was obtained after using 0.2 mmol·L-1 IPTG as inducer and culturing at 33℃ for 6 h. The refolding yield of rt-PA was up to 87.2% under optimal condition: 50 μg·ml-1 denatured rt-PA, p H 10.0, 1 mmol·L-1 GSH and ratio of GSH to GSSG 8. The key factors affecting refolding of high concentration protein were initial p H and GSH concentration, and specific bioactivity of rt-PA could reach 7.54×104 IU·mg-1 after refolding at protein concentration of 800 μg·ml-1. Fluorescence spectra indicated that structural conformation of refolded reteplase was identical with its native state.

[1]  J. A. Nicholas Management of postoperative complications: cardiovascular disease and volume management. , 2014, Clinics in geriatric medicine.

[2]  V. Gawryszewski,et al.  Mortality due to cardiovascular diseases in the Americas by region, 2000-2009. , 2014, Sao Paulo medical journal = Revista paulista de medicina.

[3]  M. Rabbani,et al.  COMPARISON OF THE CYTOPLASMIC AND PERIPLASMIC PRODUCTION OF RETEPLASE IN Escherichia coli , 2013, Preparative biochemistry & biotechnology.

[4]  Y. Guan,et al.  Statistical optimization and multiple objective programming of lysozyme refolding catalyzed by recombinant DsbA in vitro , 2012 .

[5]  N. Wang,et al.  Soluble expression of active recombinant human tissue plasminogen activator derivative (K2S) in Escherichia coli , 2011, Pharmaceutical biology.

[6]  Xinli Lin,et al.  The high pH and pH-shift refolding technology. , 2010, Current pharmaceutical biotechnology.

[7]  Liang Bu-feng Comparative Study on Assay Methods for Reteplase Activity , 2007 .

[8]  Song Xin-rong Study on expression, renaturation and purification of reteplase , 2004 .

[9]  G. Yi Minichaperone (GroEL191~345)-mediated In vitro Refolding of Recombinant Human Interferon-γ Inclusion Body , 2004 .

[10]  E. Topol A comparison of reteplase with alteplase for acute myocardial infarction. , 1998, The New England journal of medicine.

[11]  T. Investigators,et al.  A comparison of reteplase with alteplase for acute myocardial infarction , 1997 .

[12]  J. Chaudhuri,et al.  Protein folding in vivo and renaturation of recombinant proteins from inclusion bodies , 1996, Molecular biotechnology.

[13]  P. Goodenough,et al.  Isolation, renaturation, and formation of disulfide bonds of eukaryotic proteins expressed in Escherichia coli as inclusion bodies , 1993, Biotechnology and bioengineering.

[14]  R. Rudolph,et al.  Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. , 1992, Protein engineering.

[15]  A. Wittwer,et al.  Secretion of active kringle-2-serine protease in Escherichia coli. , 1990, Biochemistry.

[16]  Fan Chung Graham,et al.  Optical orthogonal codes: Design, analysis, and applications , 1989, IEEE Trans. Inf. Theory.

[17]  G. Volckaert,et al.  Cloning of cDNA coding for human tissue-type plasminogen activator and its expression in Escherichia coli. , 1986, Molecular biology & medicine.

[18]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[19]  P. Seeburg,et al.  Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli , 1983, Nature.

[20]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.